Liquidia Corporation Common Stock
LQDAStock
$75.27+435.84%52W
Market Cap$6.91B
P/E—
Div yield—
Beta0.58
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)141.43%
Price vs S&P 500 (4W)13.72%
VGM Score66.11
Market Capitalization$6.91B
Earnings Surprise History
Q1 260.52est. 0.42
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.36
4.21
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LQDALiquidia Corporation Common Stock | F | A | A | $75.27 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Liquidia Corp is a biopharmaceutical company focused on pulmonary hypertension and related lung diseases. The company leverages proprietary PRINT technology to engineer uniform drug particles, enabling its lead product YUTREPIA (treprostinil) inhalation powder, while also generating revenue from Treprostinil Injection sales.